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1. Introduction 
Age-related macular degeneration (AMD) is the most common cause of legal blindness 
among those over 65 years of age in the United States (Mitchell et al., 1995; Klein et al., 
1992). It is also a debilitating disease on central vision in patients over 50 years old (Ambati 
et al., 2003). As the baby boom generation ages, the incidence of AMD is expected to triple 
by the year 2025. It was first described in the medical literature as symmetrical central 
choroidoretinal disease occurring in senile persons (Hutchison 1875). It was not until 1980 
that AMD was regenerated to be a significant cause of blindness in the United States 
(Leibowitz et al., 1980). Even though the prevalence of AMD is highest among Caucasians in 
western countries, Asians are as high as Caucasians in the development of AMD (Wang et 
al, 2010). In 2004, WHO estimated that there are 14 million persons worldwide suffering 
from blindness or severely impaired vision because of AMD. As the population in the 
Western World is growing older, the morbidity of losing the ability to read and drive 
resulting from AMD is becoming increasingly apparent (Klein, 1997). A 2004 analysis 
reported that among Americans over the age of 40, AMD and/or geographic atrophy were 
present in at least one eye in 1.47% of the population (Friedman et al., 2004). By the year 
2020, there may be a 50% increase in the incidence of AMD. The study predicted that as a 
result of the rising prevalence of AMD, the number of blind people in the U.S. could 
increase by as much as 70% by 2020 (Congdon et al., 2004). Because of the enormous impact 
of AMD on the aging population, much public attention and research has been focused on 
this condition in the past decade.  
The therapy that could treat patients at the dry AMD stage and prevent its progression have 
a huge impact in reducing the incidence of blindness, improving the quality of life and 
reducing the social costs of AMD, which equals to approximately $30 B in GDP annually in 
the year 2003.  
AMD occurs initially in a “dry” form with pathological changes in the retinal pigment 
epithelium (RPE) and drusen accumulation and can progress to geographic atrophy (GA) 
(90%) and/or “wet” form of AMD (10%) with choroidal neovascularization (CNV) (Klein, 
1997). The breakdown of Bruch’s membrane under RPE serves as an entrance for new and 
immature choroid vessels to grow into the subretinal space that leads to the formation of 
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CNV (Klein, 1997; Lin and Chiou, 2008; Algveve and Seregard, 2002; Joussen, 2004). CNV 
can leak fluid as well as hemorrhage in the subretinal space resulting in blurry vision, visual 
distortion and sudden loss of vision (Nowak, 2006). If left untreated, these lesions progress 
to form an organized fibrous scar, termed diciform scar, which results in irreversible central 
vision loss.  
The precise etiology is poorly understood despite intensive researches. Thus, we have 
limited choices of treatment for this kind of disease. Available treatment can be grouped 
into two major categories: physical and pharmacological (chemical) therapies. The former 
received extensive attention with little success whereas the latter attract new attention with 
great hope of success.  
2. Etiology and pathogenesis of dry AMD 
Drusen is a typical clinicopathologic entity in dry AMD, which causes the changes of retinal 
pigment epithelium (RPE) and Bruch’s membrane (BRM). Drusen is deposited in between 
the basement membrane of RPE and BRM or external to BRM (Hope et al., 1992). The 
prevalence and severity of drusen formation in the eyes are linearly related to the 
progression of AMD. Oxydative stress has long been linked to age-related degenerative 
diseases and is implicated in the pathogenesis of AMD. The oxidative damage is likely to be 
the photo reactive pigments which accumulate progressively and constitute the lipofuscin of 
RPE cells (Imamura et al., 2006; Zhou et al, 2006).  
The two major carotenoids in the human macula and retina are lutein and zeaxanthin. 
Lutein and zeaxanthin are deposited at an up to 5 fold higher content in the macular region 
of the retina as compared to the peripheral retina. Several functions of these pigments have 
been hypothesized and these include limitation of the damaging photo-oxidative effects of 
blue light through its absorption, reduction of the effects of light scatter and chromatic 
aberration on visual performance, and protection against the adverse effects of 
photochemical reactions because of the anti-oxidant properties of the carotenoids. So it has 
been further hypothesized that dietary supplementation with lutein and/or zeaxanthin 
might protect the retina and/or delay the progression of AMD (Mozaffarieh et al., 2003). 
Data from the Age-Related Eye Disease Study (AREDS) suggests that supplements that 
contain carotenoids, anti-oxidant vitamins A, C, and E, and minerals, such as zinc, showed a 
25% decrease in the rate of progression to aggressive AMD among high risk patients 
(AREDS Report, 2001). The findings of the Lutein Anti-oxidant Supplementation Trial 
(LAST), a prospective, 12-month, randomized, double-masked, placebo-controlled trial, also 
support a possible therapeutic role of lutein in AMD (Richer et al., 2004). However, the 
controversial evidence also exists. The information available provides an indication that the 
carotenoids, lutein and zeaxanthin, may play a role in modulating the course of AMD, yet 
critical evidence of the beneficial effect has not been found, and crucial information for the 
most effective design of clinical trials is needed.      
Similar to drusen, basal laminar deposit (BLD) is another typical sign of AMD development 
and led by extracellular deposit. BLD is located between the cell membrane of RPE and its 
basement membrane (Green and Enger, 1993; Kliffen et al., 1997). The pathogenesis of BLD 
could be enhanced by a high fat/cholesterol (HFC) diet. The accumulation of lipid particles 
in BRM is often associated with vascular endothelial growth factor (VEGF) expression and 
eventual development of CNV in wet AMD (Rudolf et al., 2005).  
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VEGF has a high degree of selectivity to endothelial cells, reciprocal oxygen regulation, 
diffusible to its target through extracellular secretion, and affecting multiple components of 
angiogenesis (endothelial cell proliferation, survival and migration) as well as vascular 
permeability (Ambati et al., 2003b). There is a lot of evidence showing a putative role of 
VEGF in CNV formation. Intravitreous injection of an anti-VEGF pegylated aptamer, a 
synthetic RNA compound specifically designed to bind to extracellular VEGF, stabilized or 
improved vision in 87.5% of patients with subfoveal CNV 3mo after treatment. However, 
elimination of VEGF threatens the normal survival of choriocapillaries, which is the trigger 
of the AMD to begin with. Thus, VEGF inhibitors are double blade swords, which make the 
control of VEGF levels during the treatment of AMD rather difficult. Inflammation and 
compromised immune systems are also implicated in the pathogenesis of dry AMD. As a 
result, anti-inflammatory agents, such as steroids, are frequently tried for the treatment of 
dry AMD. More specifically, complement components such as C3 and C5 are constituents of 
drusen in AMD patients (Ambati et al., 2003a). Others, such as interleukin-1, interleukin-6, 
and tumor necrosis factor (TNF) are implicated to develop dry AMD as well. Thus, 
interleukin-1 blockers have been tried in the dry AMD animal models as well.  
The anti-angiogenic effect of corticosteroids has a dual mechanism. Not only do 
corticosteroids inhibit inflammation, but they also affect vascular endothelial cell 
extracellular matrix (ECM) turnover (Kaven, et al., 2001; Danis, et al., 2000). Similarly, 
corticosteroids decrease RPE cellular migration and proliferation by effecting a diminished 
enzymatic degradation of ECM components.  
Invasion and migration of endothelial cells through the extracellular matrix during 
angiogenesis are orchestrated by the integrin family of cell adhesion molecules. They 
facilitate migration by interacting with adhesion proteins in the ECM, such as collagen, 
fibronectin, fibrinogen, laminin, vitronectin and von Willebrand factor. The process of 
interacting with adhesion proteins was potentiated by the secretion of matrix 
metalloproteinases (MMPs), a family of proteolytic enzymes that degrade basement 
membrane and extracellular matrix proteins, modulated by tissue inhibitors of 
metalloproteinases (TIMPs) (Ambati, et al., 2003b).  
Drugs, which can change the construction of ECM or change the balance of MMPs and 
TIMPs, may have effects on angiogenesis process. Integrin alpha(v) beta3 is predominately 
expressed on endothelial cells in choroidal neovascularization (CNV). N-Biphenyl sulfonyl-
phenylalanine hydroxamic acid (BPHA) is a synthetic, selective inhibitor of matrix 
metalloproteinase (MMP)-2, -9, -14. Oral administration of BPHA can reduce experimental 
laser-induced choroidal neovascularization (Kohri, et al., 2003). The binding of urokinase 
plasminogen activator (uPA) and its receptor (uPAR) triggers twin cascades of events 
during cancer research, the first of which is destruction of the extracellular matrix, and the 
second is intracellular signaling to program gene expression leading to cell migration, cell 
invasion, metasis, and angiogenesis. Overexpression of uPA/uPAR system has been shown 
in surgically excised CNV, and in laser-induced CNV. The octapeptide A6 is derived from 
the non-receptor-binding regulation of uPA. Subretinal injection of adenoviral or adeno-
associated viral vectors have been used to transform the RPE into a factory for sustained 
local delivery of a drug or gene in experimental models of CNV. Angiostatin (act as a VEGF 
scavenger), TIMP-3. PEDF has been tested and showed inhibition of development of CNV in 
animal models (Ambati, et al., 2003b). An antiangiogenic activity that may last for several 
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months after a single intravitreous injection of doses greater than 10(8) pu of AdPEDF. 11 
have been reported. This study showed that adenoviral vector-mediated ocular gene 
transfer is a viable approval for the treatment of neovascular AMD (Rasmussen et.al., 2001; 
Campochiaro et al., 2006).  
In addition to age, high fat diet, light oxidation, and inflammation, the factors of smoke, 
alcohol, and gene are frequently questioned. Cigarette smoke has been indicated by 
epidemiologic studies that it is the single greatest environmental risk factor for both dry and 
wet AMD (Evans, 2001). Mice experiments with inhaled cigarette smoke resulted in the 
formation of such-RPE deposits, thickening of BRM and accumulation of deposits, within 
BRM’s membrane (Marin-Castano et al., 2006). On another experiment, mice were fed with 
nicotine in drinking water, the results showed nicotine increased the size and severity of 
experimental CNV formation (Suner, 2004).  
The influence of alcohol on the development of CNV in wet AMD was studied by Bora et al 
(2006). The results showed that the activity of fatty acid ethyl ester synthase (FAEES) 
activity increased 4-fold in the choroid of alcohol treated rats as compared to controls. 
Further, the amount of ethylesters produced in the choroid was 10-fold higher in alcohol fed 
rats than the controls. The size of the CNV formation induced by laser treatment increased 
by 28% due to alcohol treatment.  
In addition to environmental factors, gene also plays an important role in the development 
of dry AMD. Thus, some animal models used for AMD studies are transgenic mice treated 
with blue-green light (Espinosa-Heldmann et al., 2004).  
There are some diseases which are similar to AMD. They include Stargardt macular 
dystrophy (STGD) and Sorsby’s fundus dystrophy (SFD). STGD is characterized as dry 
AMD by accumulation of high level of lipofuscin in the RPE. It precedes to degeneration of 
photocells in the macular and atrophy of RPE (Karan et al., 2005; Raz-Prag et al., 2006). SFD 
is a rare autosomal dominant disorder that results in degeneration of the macular region, 
which leads to rapid loss of central vision like wet AMD (Li et al., 2005).  
Most importantly, the choroidal blood flow of dry AMD and STGD is compromised and 
significantly lower than in normal eyes. (Grunwald et al., 2003, 2005) As a result, all 
metabolic wastes produced from oxidation, inflammation, aging, complement components, 
cytokines, cigarette smoke, nicotine, high lipid, alcohol and anything else are accumulated 
in RPE cells and BRM which trigger dry AMD and eventually wet AMD or GA. On the 
opposite direction, nutrient supply to BRM, RPE and photo cells at macula are markedly 
reduced which facilitate the worsening of dry AMD (Jiang and Chiou, 2007).  
It is noteworthy that choroidal blood flow is found to be impaired by every method used to 
quantify it in the aging eye and in age-related macular degeneration: flourescein and 
indocyanine green angiography, color Doppler imaging, laser Doppler flowmetry, and 
pulsatile ocular blood flow (Freidman, 2000). The vascular model of AMD suggests that the 
elevation of intravascular pressure is the crucial hemodynamic factor in age-related macular 
degeneration. AMD is the result of the accumulation of lipids in the sclera and in Bruch’s 
membrane, progressively increasing the stiffness of these tissues, and increasing the 
postcapillary resistance of the choroidal vasculature. In addition to decreasing choroidal 
blood flow, the increase in resistance tends to elevate the hydrostatic pressure of the 
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choriocapillaries, enhancing leakage and deposition of extracellular proteins and lipids, 
particularly in the posterior pole. These deposits take the form of basal deposits within 
Bruch’s membrane and of drusen, which can comprise the overlying retinal pigment 
epithelium and cause geographic atrophy of RPE. The progressive deposition of lipid in 
Bruch’s membrane results in the degeneration of elastin and collagen, and ultimately 
calcification. The combination of elevated choriocapillary pressure, vascular endothelial 
growth factor, and a break in a calcified Bruch’s membrane causes choroidal 
neovascularization in the neovascular form of AMD. Drusen, as well as the decrease in 
choroidal blood flow may be epiphenomena (Friedman, 2000; 2004). Vasoactive agents that 
selectively decrease postcapillary choroidal resistance may prevent the development of 
CNV. Drugs working in this field may provide a new way for AMD treatment.  
3. Treatment of dry AMD with physical means 
Treatment of AMD was initially focused in wet AMD and dry AMD was left untreated 
because no effective method was available then. Drusen is a marker for dry AMD as the size 
and number of drusen are proportionally related to the progression of the disease. However 
it was not clear whether it had a role in the pathogenesis of the disease until 2006 (CAPT) 
when laser therapy was applied to treat more than 1,000 patients in one eye and the other 
eye serving as the control. It was found that laser therapy had neither beneficial nor harmful 
effect for these patients, if any. The laser’s energy can disrupt Bruch’s membrane which 
loses the ability to prevent the growth of CNV under the retina, thus converting dry AMD to 
wet AMD (CAPT, 2006). On the other hand, laser therapy seems to delay the development 
of CNV by 6 months in studies, including patients with unilateral advanced AMD (Owen et 
al., 2006; Frikerg et al., 2006). In conclusion, presence and/or elimination of drusen with 
laser treatment did not affect the visual acuity, indicating that dry AMD cannot be treated 
with physical means at the present time.    
4. Treatment of dry AMD with pharmacological agents 
Most research and developments of dry AMD are focused on the prevention of metabolic 
wastes production with limited success. This is mainly because the production of metabolic 
wastes comes from numerous sources, including oxidation, aging, complement components, 
cytokines, inflammations, PEDF, VEGF, ECM turnover and the like. Thus, a complete 
inhibition of one branch of all pathogens can suppress the progression of dry AMD at only 
around 20% at best, which falls to the borderline efficacy only. Besides, metabolic wastes are 
normal products of physiological procedures of the body and complete inhibition of normal 
metabolism could result in other various pathological side effects. Further, visual acuity 
does NOT change significantly during the progression of dry AMD, thus, selection of proper 
end points to evaluate drug efficacy in the clinical trials are very difficult if not impossible.  
4.1 Choroidal blood flow facilitators  
Although fruitful progress has been made in the treatment of wet AMD, the treatment of 
dry AMD is still in the desert stage. There is no single drug available in the whole world for 
the treatment of dry AMD. Since 90% of AMD patient population is in the dry stage, there is 
active research carried out at the present time at different stages of research and 
development (Zou and Chiou, 2005).  
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A novel idea to solve the problem has been developed recently by Chiou in Texas A&M 
Health Science Center. He based on the risk factor of dry AMD as a reduction of choroidal 
blood flow (Friedman, 2000; Grundwald et al., 2003; 2005; Xu et al., 2010; Figueroa et al., 
2006; Metelitsina et al., 2006), which lead to the accumulation of all waste products 
regardless of where they came from, including aging, oxidation, inflammation, complement 
components, VEGF, PEDF, cytokines and the like. Thus, instead of solving problems 
individually by using inhibiting/blocking agents of aging, oxidation, inflammation, 
complement components, VEGF, PEDF and cytokines, all waste products will be eliminated 
by improved choroidal circulation. Further, nutrients will be replenished to BRM, RPE, and 
photocells via improved choroidal circulation in macula to improve the vision.  
In order to prove the concept that the disease severity of dry AMD is inversely proportional to 
choroidal blood flow (CBF), drugs that can facilitate CBF were identified with ocular 
hypertensive rabbits. The CBF was measured precisely with colored microsphere method. 
Drugs which can increase CBF were then administered to AMD rat models, including NaIO3-
induced and laser-induced AMD models. The former was used to prevent/reverse 
degeneration of RPE by drugs, representing the treatments of dry AMD. The latter was used to 
show the prevention of conversion of dry to wet AMD after the Bruch’s membrane was broken 
down by laser treatment. It was interesting to note that those agents which can facilitate CBF 
can prevent/reverse AMD induced  by NaIO3 and/or laser beam. Those agents which did not 
improve CBF showed no effect on the AMD development. All drugs were administered with 
eye drops without preservatives in the ophthalmic solution. Phase I clinical trials and proof of 
the concept of MC1101 (MacuClear) in human patients had been carried out with encouraging 
results showing no major side effects observed and the drug can reach the back of the eye to 
facilitate CBF. If preclinical animal data are good indicators, it would most likely show drug 
efficacy in preventing/reversing the progression of dry AMD with these agents.  
Numerous agents that can increase choroidal blood flow in rabbit eyes have been tested in 
dry AMD animal models. Among them, some were found to be quite efficacious in 
inhibiting the development of dry AMD. They include, but are not limited to, hydralazine 
(Jiang and Chiou, 2008; Jiang et al., 2008; Cheng and Chiou, 2008), tetramethylpyrazine (Zou 
et al., 2007; Shen et al., 2010a), flavone (Zhuang et al., 2010a; 2010b), naringenin (Lin and 
Chiou, 2008; Shen et al., 2010b), apigenin (Zou and Chiou, 2006), quercetin (Zhuang et al., 
2011), guanabenz (Shen et al., 2011), interleukin-1 blockers (Zou et al., 2006) and D-timolol 
(Xu et al., 2005). 
Reduction in choroidal blood flow causes deposition of extracellular proteins, lipids and 
metabolic wastes in the form of basal deposits within BRM and drusen in between BRM and 
RPE. The progressive deposition of lipid in BRM results in the degeneration of elastin and 
collagen, and ultimately calcification. The combination of elevated choriocapillary pressure, 
expansion of VEGF and break in the calcified BRM causes development of CNV and wet 
AMD. Vasoactive agents, which can facilitate choroidal blood flow are believed to prevent 
the progression of dry AMD and is the major focus of the research at the present time (Zou 
and Chiou, 2005).    
4.2 Anti-oxidants  
Antioxidants are the agents most extensively studied. Lutein and zeaxanthin are two major 
carotenoids in the human macula and retina. They are deposited at an up to 5-fold higher 
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content in the macular region as compared to the peripheral retina. Because of antioxidant 
properties of carotenoids, lutein and zeaxanthin are considered to be able to protect and/or 
delay the progression of dry AMD (Mozaffarieh et al., 2003).  
Age-related Eye Disease Study (AREDS, 2001) reported that food supplements that contain 
carotenoids, anti-oxidants vitamins A, C, and E, plus minerals, such as zinc, showed a 25% 
decrease in the rate of progression to aggressive AMD among high risk patients. The 
findings of Lutein Anti-oxidant Supplementation Trial (LAST) (Richer et al., 2004) also 
support a possible therapeutic role of Lutein in AMD treatment. However, the critical 
evidence of therapeutic efficacy has not been established. 
In order to improve the initial success, AREDS-2 has been initiated with a new formulation 
for a six-year, multicenter, randomized trial. The new formula contains higher doses of 
lutein and zeaxanthin and/or Omega-3 fatty acids known as DHA and EPA. It also lowers 
the zinc from 80mg to 25mg and deletes β-carotene. Four thousand participants at ages 50 to 
85 have been enrolled and the trial will last six years. The results should come out sometime 
in the near future (Karmel, 2011).  
All agents, including hydralazine, tetramethylpyrazine, flavone, naringenin, apigenin, 
quercetin and guanabenz (Cheng and Chiou, 2008; Zou et al., 2006; 2007; Shen et al., 2010a; 
2010b; 2011; Zhuang et al., 2010a; 2010b; 2011; Lin and Chiou, 2008) presented in section 4.1 
as choroidal blood flow facilitators produce potent anti-oxidating actions as well. They can 
antagonize oxidation induced injuries on human RPE cells induced by H₂O₂, NaIO3, t-BHP, 
and the like.  
OT-551 is a piperidine derivative converted by ocular esterases to the actual metabolite, 
TEMPOL-H (TP-H) which serves as a potent free radical scavenger. It is a small molecule 
which can be administered as local eye drops (Tanito et al., 2007), OT-551 also possesses 
anti-inflammatory and antiangiogenic properties. OT-551 users are being investigated for 
the therapy of geographic atrophy in AMD. Unfortunately, the phase II trials failed to 
produce efficacy in preventing the enlargement rate of GA in AMD (OT-551, 2007). 
4.3 Anti-inflammatory agents     
Genetic association studies have shown that inflammation appears to be related to AMD 
(Patel and Chan, 2008). Further, complement factor H (CFH) was associated with an 
increased risk of developing AMD (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 
2005; Klein et al., 2005). Later studies linked AMD to even more complicated complement 
system. These studies indicated that inhibition of complement activation would be a 
reasonable strategy for the treatment of AMD. However, after a life-long damage on 
complement system, such a strategy might have little benefit on the AMD progression later 
in life (Arons, 2009). 
Regardless, active investigation was carried out and numerous complement inhibitors were 
derived for clinical trials. Among them, POT-4 (Potentia Pharmaceuticals) was developed as 
a C3 inhibitor for wet AMD. Eculizumab (Soliris, Alexion Pharmaceuticals) was developed 
as a C5 antibody for the treatment of dry AMD. Since eculizumab is a monoclonal antibody, 
it has to be administered via intravenous infusion to patients with GA or high risk drusen. 
ARC-1905 (Ophthotech) is an anti-C5 aptamer administrated via intravitreal injection for 
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dry and wet AMD. Another drug, anti-Complement Factor D antibody Fab (FCFD4514S) 
(Genetech/Roche) is in a phase II trial. 
For preclinical R&D, JPE (Jerin: Ophthalmic) is developed with peptidomimetic molecular 
antagonist against C5a receptor. Interleukin-1 blockers (MacuClear) are also under 
investigation as eye drops for treatment of dry AMD. 
For non-specific immune suppression for the treatment of dry AMD, subcutaneous 
glatiramer acetate (Copaxane, Teva Pharmaceuticals), intravitreal fluocinolone acetonide 
(Iluvein implant, Alimera Science) and subcutaneous sirolimus (Rapamycin, MacuSight) are 
under investigation (Arons, 2009). 
4.4 Miscellaneous agents 
Fenretinide (ST-602, Sirion Therapeutics) is an oral compound developed to slow down the 
progression of GA in AMD. It aims to reduce the accumulation of toxins which are end 
products of retinol (Vitamin A) related biochemical process. These toxins are accumulated in 
the form of lipofuscin when the elimination process is reduced such as in dry AMD and 
Stargardt’s disease (Radu et al., 2005; Study of Fenretinide, 2007). Instead of slowing down 
the toxins productions, MC1101 (MacuClear) aims to facilitate the excretion of toxins by 
increasing the choroidal circulation (See Section 4.1).  
Ciliary neurotrophic factors (CNTF, Neurotech Pharmaceuticals) have been developed to 
retard the progression of neurodegenerative diseases (A Phase II study, 2007). CNTF has 
been shown to reduce motor neuron loss in mouse and ciliary ganglion neurons in chick 
eyes. CNTF is delivered by genetically engineered cells that are housed in a patented 
delivery system called Encapsulated Cell Technology (ECT). They are surgically implanted 
through the pars plana into the vitreous and anchored to the sclera. It is designed to bypass 
the blood retinal barrier to reach the back of the eye (NTC201) (ECT Technology, 2007). 
Drugs which can change the construction of extra cellular matrix (ECM) or change the 
balance of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases 
(TIMPs) may have an effect on angiogenesis process as well (Berglin et al., 2003). These 
drugs are called ECM modifiers and are still in the experimental stage of development.   
5. Clinical protocols for anti-dry AMD drug studies 
There are at least two major obstacles which hinder the development of drugs for the 
treatment of dry AMD. First, the long time period that is required to observe progression of 
the disease (Csaky et al., 2008; AREDSRG, 2001), which discourages researchers as well as 
investors to get involved. Second, the clinical endpoints to show drug efficacy other than 
visual acuity are difficult to be determined. There are several promising methods under 
consideration and if approved by FDA, they can facilitate the drug evaluation and 
development in the future (FDA, 2008a; 2008b).   
Dry AMD is an unique chronic disease whose visual acuity does not change much during 
the early stage of the progression of the disease. Its change does not parallel to the 
worsening of visual acuity until the late stage of the disease. Consequently, the efficacy of 
drug action to treat dry AMD is impossible to be assessed based on the changes in visual 
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acuity. This is very different from the assessment of wet AMD drug actions, as the 
progression of wet AMD is parallel to the loss of visual acuity. Prolongation of dark 
adaptation is closely correlated to the severity of AMD (Jackson and Edward, 2008; Owsley 
et al., 2006; Jackson et al., 2002). Dark adaptation is strongly impacted in AMD long before 
there is any significant loss of visual acuity (Jackson and Edward, 2008). Thus, measurement 
of dark adaptation is one of the workable ways to measure the drug efficacy for the 
treatment of dry AMD. The commercially available prototype dark adaptometer (AdaptRx, 
Apeliotus Technologies Inc, Atlanta, GA) is now available. 
It has been found that rod photoreceptor degeneration precedes cone degeneration in early 
AMD (Owsley et al., 2001; Curcio et al., 1996; Steinmetz et al., 1993; Chen et al., 2004; 
Jackson et al., 2004) and rod dysfunction may contribute to the later degeneration of cones 
because of their inter-dependence (Mohand-Said et al., 2001; 1998; Hicks and Sahel,1999).  
A ten-item night vision questionnaire (NVQ-10) has been developed by Ying et al (2008). 
Analysis of NVQ-10 implies that the wet AMD and GA may derive from two different 
disease physiological processes. Because of the ease of assessment, as compared to dark 
adaptation measurement with machine, assessing night vision symptoms may be useful in 
identifying patients with early or intermediate AMD at relatively high risk of progression 
(Ying et al., 2008).   
Accumulation of the number and size of drusen is another parameter used to measure the 
progression of dry AMD. Since the change in drusen deposits is very slow and difficult to 
note subjectively, Matched Flicker (EyelC.com) has been developed to record the changes 
objectively and precisely. Basically, the precise high-tech use in the space science to record 
minute changes occurred in the sky at any time period has been applied to measure the 
changes of drusen occurred in the fundus of the same eye. Basically, two retinal images of 
the same eye from virtually any source can be loaded into Matched Flicker and the changes 
can be brought to life and observed as easy-to-detect motion. Since very minute change in 
drusen accumulation can be detected with the machine precisely and objectively, it allows to 
shorten the time to detect changes in drusen deposits as compared to inaccurate subjective 
observation with naked eyes in the past. As a result, clinical study of drug efficacy in 
slowing down the rate of drusen accumulation can be accomplished easily.  
Optical Coherence Tomography (OCT) is an advanced technology that allows researchers to 
measure the increase in volume and area of drusen over time (Yehoshua et al., 2009; OCT, 
2011). Information of detailed theory and selected application is available (OCT, 2011) and 
Spectral Domain OCT (SD-OCT) is particularly useful for monitoring drusen changes in 
volume and area which can be related to the progression of dry AMD (Yehoshua et al., 
2009). This can be used as a novel clinical trial end point for investigation therapies of dry 
AMD.  
RPE are critical cells to maintain healthy function of Bruch’s membrane and photocells. The 
degeneration of RPE can be detected by measurement of the c-wave of ERG (Jiang and 
Chiou, 2007; Peachey et al., 2002). The suppression of c-wave is proportionally related to the 
deterioration of RPE in dry AMD.  
A useful tool for determining patients’ vision related function has been developed (Kokame, 
2008) to allow the improved sensitivity for detection of even a slight change in visual 
activity in the stage of early and intermediate stages of dry AMD. The device is called NEI 
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VFQ-25 (National Eye Institute Visual Function Questionaire-25) which is responsive to 
changes in patients’ visual activity and is able to differentiate between patients who are 
responders and those who are not.  
Although NEI VFQ-25 measures patients’ subjective evaluation of their visual function and 
how impairment in vision affects their lives, it is reliable, valid and responsive as compared 
to standard measure of vision used in clinical trials such as BCVA using standardized 
ETDRS (Early Treatment of diabetic retinopathy study) vision protocols (Kokame, 2008). 
The NEI VFQ-25 showed a large separation between the groups with improved BCVA 
(gained >15 letters) stable BCVA (gain or lost 15 < letters) and worse BCVA (lost ≥ 15 
letters). It may also provide a more broad assessment of the visual function on life style and 
vision dependent activities than BCVA alone. On average, the 25-letter or better 
improvement in BCVA corresponds to an increase in the NEI VFQ-25 score of 8.2 in the 
MARINA Trial (Minimally Classic/Occult Trial of Anti-VEGF Antibody Ranibizumab in the 
Treatment of Neovascular AMD).      
Although not all dry AMD would develop into wet AMD, 10-15% of dry AMD would 
eventually be converted into wet AMD. Thus, prevention of dry AMD to be converted into 
wet AMD is also a measurement of drug action to suppress the progression of dry to wet 
AMD. Since only 10-15% of dry AMD would be converted into wet AMD, a large number of 
patients are needed for this study to see the difference in drug treatment. In short, ideal 
clinical endpoints are urgently needed for the measurement of the efficacy of new drugs for 
the treatment of dry AMD. If approved by FDA, it can shorten the measurement of drug 
efficacy to save time, effort and funds.        
6. Conclusions 
Great deals of efforts have been poured in, in order to elucidate the etiology and 
pathogenesis of the dreadful disease, age-related macular degeneration, with a hope to 
develop an effective means of treatment and/or prevention of the disease. Although the 
etiology and pathogenesis have been largely revealed, its treatment with physical means has 
since failed and receded to the second line of treatment options. Fortunately, 
pharmacological agents are now available for the treatment of wet AMD. However, wet 
AMD is the very late stage of AMD and is too late to save the eyesight for normal daily 
function. Besides, wet AMD consists of only 10-15% of total AMD patients. Thus, 
developing efficacious drugs for dry AMD is most urgently needed. The key stage of the 
treatment of AMD is obviously at the early stage or dry phase of the disease. There are 
numerous groups of scientists working very hard to develop an efficacious drug yet none 
have succeeded as of yet.  
The major obstacles for the development of ideal drugs for dry AMD are at least two folds. 
First, AMD is a long term chronic disease with little worsening of visual acuity until the 
very late stage of the disease. Thus, the clinical end point to measure improvement of visual 
acuity by drugs at early or even middle stages of the disease is very difficult. The agents for 
improving the choroidal circulation are under investigation. Alternative end points to 
measure visual functions have been developed including the measurement of dark 
adaptation for rod cell functions, the determination of c-wave of ERG for RPE cell functions 
and macular stress test for cone cell function in the macula. Secondly, the pathogenesis of 
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the disease is closely related to numerous normal physiological functions, such as oxidation, 
aging, VEGF and PEDF expression, extracellular matrix modifications and the like. Thus, 
complete suppression of these normal functions is not only unrealistic and even detrimental 
to induce further devastating side effects. Since these factors are numerous, suppression of 
one of them can improve the disease only partially to bring it to the borderline, marginal 
improvement of the disease. The novel idea to solve the problem at the root of the disease is 
to improve the choroidal circulation which can eliminate all normal metabolic wastes from 
photocells, Bruch’s membrane and RPE cells and to furnish nutrients to these critical tissues. 
This way, the macular function will go back to normal and the AMD would be reversed or 
suppressed without further development. 
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